Striving To Treat Blinding Retinal Conditions
Striving To Treat Blinding Retinal Conditions
WHAT WE DO
ReVive Biotechnology Inc. is a preclinical company developing nano-drug delivery solutions to treat blinding diseases of the eye. We are focused on producing a nano-carrier system for delivering Oxygen to the retina. We are a multidisciplinary, technologically advanced, friendly, motivated team geared to bring advanced therapeutics to patients.
ReVive Biotechnology Inc. is a preclinical company developing nano-drug delivery solutions to treat blinding diseases of the eye. We are focused on producing a nano-carrier system for delivering Oxygen to the retina. We are a multidisciplinary, technologically advanced, friendly, motivated team geared to bring advanced therapeutics to patients.
ReVive Biotechnology Inc. is a preclinical company developing nano-drug delivery solutions to treat blinding diseases of the eye. We are focused on producing a nano-carrier system for delivering Oxygen to the retina. We are a multidisciplinary, technologically advanced, friendly, motivated team geared to bring advanced therapeutics to patients.
WHAT WE DO
We have developed proprietary nanotechnology and have advanced through the proof of concept studies for ocular hyWe have developed proprietary nanotechnology and have advanced through the proof of concept studies for ocular hypoxic conditions in an animal model. We are working through the regulatory process to achieve FDA approval for this groundbreaking therapeutic for ischemic retinal conditions. In the meantime, we are adapting our technology to wound care, blood oxygenation to bypass diseased pulmonary tissue, and adjuvant for cancer treatment.poxic conditions in an animal model. We are working through the regulatory process to achieve FDA approval for this groundbreaking therapeutic for ischemic retinal conditions. In the meantime, we are adapting our technology to wound care, blood oxygenation to bypass diseased pulmonary tissue, and adjuvant for cancer treatment.
We have developed proprietary nanotechnology and have advanced through the proof of concept studies for ocular hypoxic conditions in an animal model. We are working through the regulatory process to achieve FDA approval for this groundbreaking therapeutic for ischemic retinal conditions. In the meantime, we are adapting our technology to wound care, blood oxygenation to bypass diseased pulmonary tissue, and adjuvant for cancer treatment.
TESTIMONIALS
TESTIMONIALS
Etiam quis nibh sed dolor lacinia mollis ultricies eu libero. Nam mollis ac mauris eget rutrum. Nulla nec ipsum et ligula cursus porta id scelerisque felis. Fusce faucibus ex sed dui commodo, nec tristique odio pharetra. Nunc iaculis nisl sit amet lorem sollicitudin, id rhoncus felis sollicitudin. Proin ac ipsum sed lorem dictum dignissim. Donec sagittis molestie dui, a consectetur erat. Nam dapibus massa purus, nec finibus massa sodales non. Donec id condimentum quam. Ut quis arcu posuere, consequat lacus at, aliquam augue. Aenean sed ornare dolor. Aliquam erat volutpat. Nam suscipit, nunc in elementum consectetur, mauris tellus porta lectus, vel iaculis lectus mauris vel turpis.
Vestibulum pulvinar finibus semper. In molestie quam in cursus tincidunt. Mauris sit amet nunc sit amet ipsum lobortis convallis. Nunc in nisl at sem semper volutpat. Integer scelerisque nunc a quam lacinia maximus. Aenean arcu erat, convallis ac odio eu, sagittis congue ante. Proin vel ornare dolor. In dapibus lectus non elit pellentesque vestibulum. Vivamus orci lacus, aliquam vitae nunc quis, venenatis blandit odio. Curabitur tortor orci, posuere commodo mauris eget, molestie facilisis massa.
Vestibulum pulvinar finibus semper. In molestie quam in cursus tincidunt. Mauris sit amet nunc sit amet ipsum lobortis convallis. Nunc in nisl at sem semper volutpat. Integer scelerisque nunc a quam lacinia maximus. Aenean arcu erat, convallis ac odio eu, sagittis congue ante. Proin vel ornare dolor. In dapibus lectus non elit pellentesque vestibulum. Vivamus orci lacus, aliquam vitae nunc quis, venenatis blandit odio. Curabitur tortor orci, posuere commodo mauris eget, molestie facilisis massa.